Background: While coronary artery aneurysm is an uncommon anatomic disorder and has various forms, its clinical features and outcome and its impact on thrombus formation and the no-reflow phenomenon in the clinical setting of acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (p-PCI) have not been discussed. The purpose of this study was to evaluate whether this anatomic disorder predisposes to a high burden of thrombus formation, and subsequently leads to the no-reflow phenomenon and untoward clinical outcome in patients with AMI undergoing p-PCI. Methods and Results: In our hospital, emergency p-PCI was performed in 924 consecutive patients with AMI between May 1993 and July 2001. Of these 924 patients, 24 patients (2.6%) who had an infarct-related artery (IRA) with aneurysmal dilatation were retrospectively registered and constituted the patient population of this study. Angiographic findings demonstrated that the ectasia type (defined as diffuse dilatation of 50% or more of the length of the IRA) was found most frequently (70%), followed by the fusiform type (20%; defined as a spindle-shaped dilatation in the IRA) and the saccular type (10%; defined as a localized spherical-shaped dilatation in the IRA). The right coronary artery was the most frequently involved vessel (54.2%), followed by the left anterior descending (25.0%) and the left circumflex arteries (20.8%). Coronary angiography revealed that all of these aneurysmal IRA filled with heavy thrombus (indicated as high-burden thrombus formation). The no-reflow phenomenon (defined as ≤TIMI-2 flow) and distal embolization after p-PCI were found in 62.5 and 70.8% of the IRA, respectively. The incidence of cardiogenic shock and the 30-day mortality rate were 25 and 8.3%, respectively. The survival rate was 90.9% (20/22) during a mean follow-up of 19 ± 30 months. Conclusions: While aneurysmal dilatation of an IRA is an uncommon angiographic finding in the clinical setting of AMI, it is frequently associated with high-burden thrombus formation and has a significantly lower incidence of successful reperfusion. However, the long-term survival of these patients is excellent.

Keywords:
Acute myocardial infarction, Aneurysm, Coronary artery aneurysm, Infarct-related artery, No-reflow phenomenon
1.
Daoud AS, Pankin D, Tulgan H, Florentin RA: Aneurysms of the coronary artery: Report of ten cases and review of literature. Am J Cardiol 1963;11:228–237.
2.
Berkoff HA, Rowe GG: Atherosclerotic ulcerative disease and associated aneurysms of the coronaries. Am Heart J 1975;90:153–158.
3.
Alford WJ, Stoney WS, Burrus GT: Recognition and operative management of patients with atherosclerotic coronary artery aneurysms. Ann Thorac Surg 1976;22:317–321.
4.
Swaye PS, Fisher LD, Litwin P, Vignola PA, Judkins MP, Kemp HG, Mudd JG, Gosselin AJ: Aneurysmal coronary artery disease. Circulation 1983;67:134–138.
5.
Rath S, Har-Zahav Y, Battler, Agranat O, Rotsein Z, Rabinowitz B, Neufeld HN: Fate of non-obstructive aneurysmatic coronary artery disease: Angiographic and clinical follow-up report. Am Heart J 1985;109:785–791.
6.
Robertson T, Fischer L: Prognostic significance and coronary artery aneurysm and ectasia in the coronary artery surgery study (CASS) registry; in Shulman ST (ed): Kawasaki Disease: Proceedings of the Second International Kawasaki Symposium. New York, Liss, 1987, pp 325–339.
7.
Wang KY, Ting CT, Sutton MSJ, Chen YT: Coronary artery aneurysms: A 25-patient study. Cathet Cardiovasc Intervent 1999;48:31–38.
8.
Befeler B, Aranda JM, Embi A, Mullin FL, EI-Sherif N, Lazzara R: Coronary artery aneurysms: Study of their etiology, clinical course and effect on left ventricular function and prognosis. Am J Med 1977;62:597–607.
9.
Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, Kazue T, Eto G, Yamakawa R: Long-term consequences of Kawasaki disease: A 10- to 20-year follow-up study of 594 patients. Circulation 1996;94:1379–1385.
10.
Syed M, Lesh M: Coronary artery aneurysm: A review. Prog Cardiovasc Dis 1997;40:77–84.
11.
Morgagni JB: De sedibus et causis morborum. Venectus Tom I, Epis 27, Art 28, 1761.
12.
Smith RL, Blick EF, Coalson J, Stein PD: Thrombus production by turbulence. J Appl Physiol 1972;32:261–264.
13.
Stein PD, Sabbah HN: Measured turbulence and its effect on thrombus formation. Circ Res 1974;35:608–614.
14.
Stein PD, Sabbah HN: Turbulence blood flow in the ascending aorta of humans with normal and diseased aortic valves. Circ Res 1976;39:58–65.
15.
Yu SK, Latour JG, Marchandise B, Bois M: Shear stress-induced changes in platelet reactivity. Thromb Haemost 1978;40:551–560.
16.
Yip HK, Wu CJ, Chang HW, Chen MC, Hang CL, Fang CY, Hsieh YK, Yang CH, Yeh KH, Fu M: Comparison of impact of primary percutaneous transluminal coronary angioplasty and primary stenting on short-term mortality in patients with cardiogenic shock and evaluation of prognostic determinants. Am J Cardiol 2001;87:1184–1188.
17.
The TIMI Study Group: The Thrombolysis in Myocardial Infarction (TIMI) Trial: Phase 1 findings. N Engl J Med 1985;312:932–936.
18.
Swanton RH, Thomas ML, Coltart DJ, Jenkins BS, Webb-Peploe MM, Williams BT: Coronary artery ectasia. A variant of occlusive coronary arteriosclerosis. Br Heart J 1978;40:393–400.
19.
Markis JE, Joffe CD, Cohn PF: Clinical significance of coronary arterial ectasia. Am J Cardiol 1976;37:217–222.
20.
The Primary Angioplasty in Myocardial Infarction (PAMI) Stent Pilot Trial Investigators: Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: In-hospital and 30-day results of the PAMI stent pilot trial. J Am Coll Cardiol 1998;31:23–30.
21.
ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators: Randomized, placebo-control trial of platelet glycoprotein IIb/IIIa blockage with primary angioplasty for acute myocardial infarction. Circulation 1998;98:734–741.
22.
Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansieri M, Choussat R, Pinton P: Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895–1903.
23.
Fujii T, Ueda M, Ikura Y, Osawa M, Kawano S, Ito H, Fujii K, Yoshiyama M, Tacheuchi K, Yashikawa J: Aspiration intracoronary thrombus by RescueTM PT catheter: Histological and immunohistochemical analyses. Circulation 2002;66(suppl):I-458.
24.
Gibson CM, de Lemos JA, Murphy SA, Marble SJ, McCabe CH, Cannon CP, Antman EM, Braunwald E: Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: A TIMI 14 substudy. Circulation 2001;103:2550–2554.
25.
Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ: Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957–966.
26.
Nakagawa Y, Matsuo S, Kimura T, Yokoi H, Tamura T, Hamasaki N, Nosaka H, Nobuyoshi M: Thrombectomy with AngioJet catheter in native coronary arteries for patients with acute or recent myocardial infarction. Am J Cardiol 1999;83:994–999.
27.
Belli G, Pezzano A, De Biase AM, Bonacina E, Silva P, Salvade P, Piccalo G, Klugmann S: Adjunctive thrombus aspiration and mechanical protection from distal embolization in primary percutaneous intervention for acute myocardial infarction. Cathet Cardiovasc Intervent 2000;50:362–370.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.